Glucocorticoid treatment of polymyalgia rheumatica

Clinical and Experimental Rheumatology

Volumn 29, Issue 5 SUPPL. 68, 2011, Pages

  Caporali, R ^a   Cimmino, M A ^b   Montecucco, C ^a   Cutolo, M ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Circadian rhythms; Dehydro epiandrosterone sulphate (DHEA); Glucocorticoids; HPA; IL 6; Polymyalgia rheumatica

Indexed keywords

ANDROSTENEDIONE; CORTICOSTERONE; DEFLAZACORT; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 6; MEPREDNISONE; METHOTREXATE; METHYLPREDNISOLONE; PRASTERONE SULFATE; PREDNISOLONE; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR;

ADRENAL GLAND; AGING; ARTICLE; CIRCADIAN RHYTHM; CYTOKINE PRODUCTION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG FEVER; DRUG MEGADOSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

GLUCOCORTICOIDS; HUMANS; POLYMYALGIA RHEUMATICA;

EID: 81155125085     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. SALVARANI C, CANTINI F, BOIARDI L et al.: PMR and giant cell arteritis. Best Pract Res Clin Rheumatol 2004; 18: 705-22.
2. SOUBRIER M, DUBOST JJ, RISTORi JM: Polymyalgia reumatica: diagnosis and treatment. Joint Bone Spine 2006; 73: 599-605.
3. HEALEY LA: Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Sem Arthritis Rheum 1984; 13: 322-8. (Pubitemid 14079396)
4. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, LOPEZ-DIAZ MJ et al.: Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454-61.
5. STRAUB RH, MILLER LE, SHÖLMERICH J, ZIETZ B: Cytokines and hormones as possible links between endocrinosenescence and immunosenescence. J Neuroimmunol 2000; 109: 10-5.
6. STRAUB RH, KONECNA L, HRACH S et al.: Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (1L-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83: 2012-17. (Pubitemid 28496330)
7. STRAUB RH, GLUCK T, CUTOLO M et al.: The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumor necrosis factor) in polymyalgia rheumatica. Rheumatology 2000; 39: 624-31. (Pubitemid 30459948)
8. CUTOLO M, STRAUB RH: Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis driven disease. Clin Exp Rheumatol 2000; 18: 655-8.
9. STRAUB RH, CUTOLO M: Does stress influence the course of rheumatic diseases? Clin Exp Rheumatol 2006; 24: 225-8. (Pubitemid 44151138)
10. WALKER JG, LITTLEJOHN GO, MCMURRAY NE, CUTOLO M: Stress system response and rheumatoid arthritis: A multi-level approach. Rheumatology 1999; 38: 1050-7. (Pubitemid 29537323)
11. CUTOLO M, CIMMINO MA, SULLI A: Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford). 2009; 48: 93-5.
12. SULLI A, MONTECUCCO CM, CAPORALI R et al.: Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 307-14. (Pubitemid 43989874)
13. LI C, DASGUPTA B: Corticosteroids in polymyalgia rheumatica. A review of different treatment schedules. Clin Exp Rheumatol 2000; 18 (Suppl. 20): S56-S57. (Pubitemid 30655859)
14. DELECOUILLERIE G, JOLY P, COHEN DE LARA A, PAOLAGGI JB: Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens. Ann Rheum Dis 1988;47:733-9.
15. KYLE V, HAZLEMAN B: Treatment of polymyalgia rheumatica and giant cell arteritis I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48: 658-61. (Pubitemid 19201963)
16. CIMMINO MA, PARODI M, MONTECUCCO C, CAPORALI R: The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 2011; 12: 94.
17. LUQMANI R: Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward? Ann Intern Med 2007; 146: 674-6. (Pubitemid 351650523)
18. SALVARANI C, MACCHIONI P, TARTONI PL et al.: PMR and CGA: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987; 5: 205-15. (Pubitemid 18037233)
19. KREMERS HM, REINALDA MS, CROWSON CS et al.: Relapse in a population based cohort of patients with PMR. J Rheumatol 2005; 32: 65-73. (Pubitemid 40092593)
20. DEJACO C, DUFTNER C, CIMMINO MA et al.: Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447-53.
21. LEEB BF, BIRD HA: A disease activity score for PMR. Ann Rheum Dis 2004; 63: 1279-83.
22. BOGLIOLO L, CIMMINO MA, OLIVERI M et al.: Are long-term steroid-free remissions the rule in polymyalgia rheumatica? Results of a retrospective study on 320 patients. Ann Rheum Dis 2009; 68 (Suppl. 3): 324.
23. CHUANG TY, HUNDER GG, ILSTRUP DM et al.: Polymyalgia rheumatica: a ten-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672-80.
24. BEHN AR, PERERA T, MYLES AB: Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374-8. (Pubitemid 13037093)
25. GABRIEL SE, SUNKU J, SALVARANI C et al.: Adverse outcomes of antiinflammatory therapy among patients with polymyalgia reumatica. Arthritis Rheum 1997; 40: 1873-8. (Pubitemid 27452540)
26. CHANTLER IW, DAVIE MWJ, EVANS SF, REES JS: Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 1993; 62: 350-2.
27. AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON GLUCOCORTICOID- INDUCED OSTEOPOROSIS: Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-503.
28. GENNARI C, IMBIMBO B, MONTAGNANI M, BERNINI M, NARDI P, AVIOLI LF: Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 1984; 36: 245-52. (Pubitemid 14072389)
29. O'CONNELL SL, TRESHAM J, FORTUNE CL et al.: Effects of prednisolone and deflazacort on osteocalcin metabolism in sheep. Calcif Tissue Int 1993; 53: 117-21. (Pubitemid 23215386)
30. OLGAARD K, STORM T, WOVERN NV et al.: Glucocorticoid-induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients: a double-blind study on the high dose, long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992; 50: 490-7.
31. LUND B, EGSMOSE C, JORGENSEN S, KROGSGAARD MR: Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987; 41: 316-20.
32. CIMMINO MA, MOGGIANA G, MONTECUCCO C, CAPORALI R, ACCARDO S: Long-term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 1994; 53: 331-3. (Pubitemid 24164978)
33. KROGSGAARD MR, LUND B, JOHNSSON B: A long-term prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rheumatica. J Rheumatol 1995; 22: 1660-2.
34. KROGSGAARD MR, THAMSBORG G, LUND B: Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann Rheum Dis 1996; 55: 143-6. (Pubitemid 26054338)
35. SAVIOLA G, ABDI ALI L, EDDIN SS et al.: Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. Rheumatology (Oxford) 2007; 46: 994-8. (Pubitemid 47062510)
36. CACOUB P, CHEMLAL K, KHALIFA P et al.: Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol 2001; 28: 2474-9. (Pubitemid 33031979)
37. DASGUPTA B, GRAY J, FERNANDES L, OLLIFF C: Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone. Ann Rheum Dis 1991; 50: 942-5.
38. DASGUPTA B, DOLAN AL, PANAYI GS, FERNANDES L: An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 1998; 37: 189-95.
39. SALVARANI C, CANTINI F, OLIVIERI I et al.: Corticosteroid injection in polymyalgia reumatica: a double-blind, prospective, randomized, placebo-controlled study. J Rheumatol 2000; 27: 1470-6.
40. CIMMINO MA, MACCHIONI P, BOIARDI L, CANTINI F, PULSATELLI L, SALVARANI C: Pulse steroid treatment of polymyalgia rheumatica. Clin Exp Rheumatol 2004; 22: 381-2. (Pubitemid 38585252)
41. SPIES CM, CUTOLO M, STRAUB RH, BURMESTER GR, BUTTGEREIT F: More night than day - circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol 2010; 37: 894-9.
42. CUTOLO M, STRAUB RH, BUTTGEREIT F: Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis 2008; 67: 905-8. (Pubitemid 351956649)
43. ROCHE NE, FULBRIGHT JW, WAGNER AD, HUNDER GG, GORONZY JJ, WEYAND CM: Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36: 1286-94. (Pubitemid 23303119)
44. ALTEN R, DÖRING G, CUTOLO M et al.: Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with night time-release prednisone. J Rheumatol 2010; 37: 2025-31.
45. LUNDBERG I. HEDFORS E: Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17: 1340-5. (Pubitemid 20382862)
46. VAN DER VEEN MJ, DINANT HJ, VAN BOOMAFRANKFORT C, VAN ALBADA-KUIPFRS GA, BIJLSMA JW: Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218-23. (Pubitemid 26120700)
47. BAHLAS S, RAMOS-REMUS C, DAVIS P: Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998; 25: 99-104. (Pubitemid 28060126)
48. NARVÁEZ J, NOLLA-SOLÉ JM, CLAVAGUERA MT, VALVERDE-GARCÍA J, ROIG-ESCOFET D: Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 1999; 26: 1945-52. (Pubitemid 30007063)
49. CANTINI F, SALVARANI C, OLIVIERI I et al.: Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17-24. (Pubitemid 30644069)
50. MYKLEBUST G, GRAN JT: Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol 2001; 30: 260-7. (Pubitemid 32980337)
51. CAPORALI R, CIMMINO MA, FERRACCIOLI G et al.: Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141: 493-500. (Pubitemid 39350239)
52. SALVARANI C, CANTINI F, NICCOLI L et al.: Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005; 53: 33-8. (Pubitemid 40216349)
53. PEASE CT, HAUGEBERG G, MORGAN AW, MONTAGUE B, HENSOR EM, BHAKTA BB: Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with Polymyalgic symptoms. A prospective longterm evaluation. J Rheumatol 2005; 32: 1043-6. (Pubitemid 40828076)
54. SALVARANI C, MACCHIONI P, MANZINI C et al.: Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146: 631-9. (Pubitemid 351650518)